Four are directed against CD19 and used to treat B-cell lymphomas and ALL (Table 1), and two are directed against B-cell maturation antigens (BCMA) and used to treat multiple myeloma (Table 2). Here, CD19 is linked to acute lymphoblastic leukemia.